
Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.
Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.




